HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Zhanyang Yu Selected Research

Annexin A2 (Annexin II)

1/2021Recombinant Annexin A2 Administration Improves Neurological Outcomes After Traumatic Brain Injury in Mice.
12/2019Annexin A2 Deficiency Exacerbates Neuroinflammation and Long-Term Neurological Deficits after Traumatic Brain Injury in Mice.
12/2017Annexin A2 Plus Low-Dose Tissue Plasminogen Activator Combination Attenuates Cerebrovascular Dysfunction After Focal Embolic Stroke of Rats.
8/2015Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke.
1/2015Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy.
2/2014Effects of tissue plasminogen activator and annexin A2 combination therapy on long-term neurological outcomes of rat focal embolic stroke.
6/2013Dysfunction of annexin A2 contributes to hyperglycaemia-induced loss of human endothelial cell surface fibrinolytic activity.
10/2010Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.
6/2010Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Zhanyang Yu Research Topics

Disease

14Stroke (Strokes)
01/2020 - 06/2010
9Ischemia
01/2021 - 03/2009
7Hypoxia (Hypoxemia)
01/2021 - 01/2009
6Traumatic Brain Injuries (Traumatic Brain Injury)
01/2021 - 06/2012
6Hyperglycemia
01/2020 - 02/2012
4Alzheimer Disease (Alzheimer's Disease)
01/2020 - 01/2012
4Brain Infarction
12/2018 - 06/2010
4Embolic Stroke
12/2017 - 06/2010
3Type 2 Diabetes Mellitus (MODY)
01/2020 - 12/2018
3Neuroinflammatory Diseases
12/2019 - 06/2018
3Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
12/2018 - 06/2010
3Ischemic Stroke
12/2018 - 06/2010
3Neurodegenerative Diseases (Neurodegenerative Disease)
01/2018 - 01/2012
3Brain Injuries (Brain Injury)
03/2016 - 06/2012
2Brain Ischemia (Cerebral Ischemia)
01/2021 - 11/2019
2Brain Edema (Cerebral Edema)
01/2021 - 03/2016
2Neuroblastoma
03/2019 - 01/2018
2Nervous System Diseases (Neurological Disorders)
01/2018 - 01/2013
2Hemorrhage
08/2015 - 10/2010
2Infarction (Infarctions)
08/2015 - 02/2014
1Wounds and Injuries (Trauma)
02/2021
1Amyloidosis
01/2020
1Cognitive Dysfunction
06/2018
1Hyperlipidemias (Hyperlipidemia)
06/2018
1Inflammation (Inflammations)
06/2018
1Insulin Resistance
06/2018
1Obesity
06/2018
1Mitochondrial Diseases (Mitochondrial Disease)
04/2015
1Brain Diseases (Brain Disorder)
01/2012
1Ocular Hypertension (Glaucoma, Suspect)
12/2011
1Retinal Diseases
12/2011
1Edema (Dropsy)
06/2010
1Thrombosis (Thrombus)
06/2010

Drug/Important Bio-Agent (IBA)

12NeuroglobinIBA
01/2018 - 01/2009
10Proteins (Proteins, Gene)FDA Link
01/2021 - 06/2010
9Annexin A2 (Annexin II)IBA
01/2021 - 06/2010
8Tissue Plasminogen Activator (Alteplase)FDA Link
12/2017 - 06/2010
4Glucose (Dextrose)FDA LinkGeneric
01/2021 - 04/2015
4fibroblast growth factor 21IBA
01/2020 - 06/2018
3Oxygen (Dioxygen)IBA
01/2021 - 01/2013
3Messenger RNA (mRNA)IBA
01/2020 - 12/2018
3CytokinesIBA
01/2020 - 03/2016
3Neuroprotective AgentsIBA
12/2018 - 12/2011
2Biological ProductsIBA
02/2021 - 12/2011
2polysialyl neural cell adhesion moleculeIBA
03/2019 - 01/2018
2GlobinsIBA
01/2013 - 12/2011
1Ephrin-B2 (Ephrin B2)IBA
01/2021
1Annexin A1IBA
01/2021
1EphB2 ReceptorIBA
01/2021
1DNA (Deoxyribonucleic Acid)IBA
01/2020
1InterleukinsIBA
01/2020
15' Untranslated Regions (5' UTR)IBA
01/2020
1Amyloid (Amyloid Fibrils)IBA
01/2020
1Trace Elements (Biometals)IBA
01/2020
1Vascular Endothelial Growth Factor CIBA
11/2019
1Interleukin-1beta (Interleukin 1 beta)IBA
05/2019
1histone deacetylase 3IBA
05/2019
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
12/2018
1Matrix Metalloproteinases (MMPs)IBA
12/2017
1cadherin 5IBA
12/2017
1rat endothelial barrier antigenIBA
12/2017
1FibrinIBA
12/2017
1CollagenIBA
12/2017
1Immunoglobulin G (IgG)IBA
12/2017
1Thrombospondin 1IBA
01/2017
1Complement System Proteins (Complement)IBA
03/2016
1Evans Blue (Blue, Evans)FDA Link
03/2016
1ApolipoproteinsIBA
03/2016
1ClusterinIBA
03/2016
1Amyloid beta-PeptidesIBA
01/2016
1IronIBA
08/2015
1Therapeutic UsesIBA
08/2015
1Biomarkers (Surrogate Marker)IBA
02/2014
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2014
1SynaptophysinIBA
02/2014
1ElementsIBA
04/2012
1Superoxides (Superoxide)IBA
12/2011
1Adenosine Triphosphate (ATP)IBA
12/2011
1Arachidonate 15-Lipoxygenase (Arachidonate 15 Lipoxygenase)IBA
06/2010
1Apoptosis Inducing FactorIBA
06/2010
1FibrinolysinFDA Link
06/2010

Therapy/Procedure

12Therapeutics
12/2018 - 06/2010
2Thrombolytic Therapy
01/2014 - 06/2010
1Treatment Delay
08/2015